EMG for Uterotonic Efficiency Estimation

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

Studies found conflicting results on efficacy of uterotonic agents used to prevent and treat uterine atony, the most common cause of postpartum hemorrhage. Uterine EMG can be used to objectively assess myometrial contractility and, consequently, efficacy of different uterotonics.

The investigators are planning a single-center, randomized, open-label trial to compare uterine EMG parameters in women receiving oxytocin vs. those receiving carbetocin after cesarean delivery.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Medical Centre Ljubljana
• Treatments: Carbetocin; Oxytocin

Criteria

Inclusion Criteria:

• Patients with singleton pregnancies at term ( ≥37 weeks of pregnancy) scheduled for elective cesarean section after one previous cesarean section.

Exclusion Criteria:

• Contraindications for any of the study drugs.

• Anaemia Hb <100g

• History of postpartum hemorrhage

• Uterine fibroids

• Blood clotting disorder

• Placental disorder ( Placenta previa, placenta accreta)

• Preeclampsia

• Renal, cardiac or hepatic dysfunction.